StockData
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP) shareholders

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$40.15−0.22 (-0.54%)

Close on Nov 17, 2026Market cap $3.88BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
78.9%
76M of 97M shares
Institutional holders
522
82 new, 47 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
0 buys · 30 sales
Net sold $17.94M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Catherine D. Wood
Joint filing with ARK Investment Management LLC (11.79%)
11,313,62311.79%13G (passive) amendmentMar 31, 2026
ARK Investment Management LLC
Joint filing with Catherine D. Wood (11.85%)
10,165,40011.85%13G (passive) amendmentMar 31, 2025
BlackRock, Inc.7,987,2628.30%13G (passive) amendmentJun 30, 2026
Orbis Investment Management Ltd5,433,3445.60%13G (passive) amendmentJun 30, 2026
State Street Corporation4,994,0475.20%13G (passive)Sep 30, 2026
Capital World Investors4,929,4285.10%13G (passive)Mar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of CRSPValueChange% of portfolio
ARK Investment Management LLC9,460,9399.78%$516.00M−1,852,6843.35%
BlackRock, Inc.8,348,9778.63%$455.35M+668,9040.01%
Orbis Allan Gray Ltd5,449,1615.64%$297.20M−656,8501.02%
Capital World Investors4,749,5254.91%$259.04M+24,4880.03%
State Street Corp4,321,6664.47%$235.70M+339,1660.01%
GSK plc3,220,6273.33%$175.65M–29.17%
Geode Capital Management, LLC2,509,9152.60%$136.92M+132,7510.01%
T. Rowe Price Investment Management, Inc.2,053,0172.12%$111.97M−899,5780.07%
Sr One Capital Management, LP2,038,7632.11%$111.19M–10.70%
Two Sigma Investments, LP1,988,6212.06%$108.46M+505,5700.08%
FMR LLC1,908,5031.97%$104.09M−46,1910.00%
Sumitomo Mitsui Trust Holdings, Inc.1,720,7341.78%$93.85M−133,1410.05%
Nikko Asset Management Americas, Inc.1,720,0971.78%$93.76M−133,7781.21%
EcoR1 Capital, LLC1,389,2761.44%$75.77M–3.68%
UBS Group AG1,317,4991.36%$71.86M−445,0310.01%
Capital International Investors1,268,4071.31%$69.18M+81,6130.01%
Vanguard Capital Management LLC1,181,8471.22%$64.46M+39,3040.00%
Bank Of America Corp /De/1,155,1051.19%$63.00M+172,0330.00%
NEA Management Company, LLC1,058,5701.09%$57.73M–3.64%
Charles Schwab Investment Management Inc1,057,8371.09%$57.69M+18,4880.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202652276M78.9%82 / 156142 / 476M7M
Q1 202649377M79.8%80 / 176117 / 5813M12M
Q4 202548078M81.1%96 / 150128 / 5211M5M
Q3 202544073M75.3%73 / 146120 / 589M9M
Q2 202543373M75.3%101 / 127101 / 6015M7M
Q1 202539665M66.9%55 / 123102 / 598M8M
Q4 202440465M66.8%66 / 114122 / 7010M5M
Q3 202441660M62.3%45 / 132131 / 737M4M
Q2 202444960M62.0%49 / 159129 / 755M7M
Q1 202448262M63.9%74 / 159137 / 5711M6M
Q4 202347256M58.4%120 / 136124 / 456M5M
Q3 202340755M56.8%45 / 157100 / 523M3M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Samarth KulkarniChief Executive Officer, Director397,5210.41%Oct 28, 2026
Sivakesava SakhamuriChief Technical Officer––Nov 6, 2026
Naimish PatelChief Medical Officer19,3570.02%Oct 28, 2026
James R. KasingerGeneral Counsel and Secretary95,8570.10%Oct 28, 2026
Andrew Jacob SilverChief Financial Officer––Oct 28, 2026
Raju PrasadChief Financial Officer14,8150.02%Aug 11, 2026
Julianne BrunoChief Operating Officer17,6320.02%Mar 24, 2025
Simeon GeorgeDirector2,054,2492.12%Oct 16, 2026
Ali BehbahaniDirector3450.00%Sep 21, 2026
John GreeneDirector7,0000.01%Jun 9, 2026
Katherine A. HighDirector––Jun 9, 2026
Douglas A. TrecoDirector22,0000.02%Jun 9, 2026
Briggs MorrisonDirector5,2090.01%Jun 9, 2026
Christian RommelDirector––Jun 9, 2026
Sandesh MahatmeDirector––Jun 9, 2026
Maria FardisDirector––Jun 9, 2026
Harold Edward FlemingDirector––Jun 9, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Samarth Kulkarni
Chief Executive Officer, Director
Oct 19, 2026Sale−47,837$49.78$2.38M311,899
Samarth Kulkarni
Chief Executive Officer, Director
Oct 16, 2026Option exercise+100,000––359,736
Simeon George
Director
Oct 14, 2026Sale(10b5-1 plan)−14,514$49.63$720.37K15,486
Simeon George
Director
Oct 14, 2026Option exercise+30,000$14.00$420.00K30,000
James R. Kasinger
General Counsel and Secretary
Oct 14, 2026Sale−1,040$49.26$51.23K95,857
Samarth Kulkarni
Chief Executive Officer, Director
Oct 14, 2026Sale−4,098$49.26$201.87K259,736
James R. Kasinger
General Counsel and Secretary
Oct 13, 2026Option exercise+2,113––96,897
Samarth Kulkarni
Chief Executive Officer, Director
Oct 13, 2026Option exercise+8,333––263,834
James R. Kasinger
General Counsel and Secretary
Oct 6, 2026Sale(10b5-1 plan)−1,990$60.04$119.48K94,784
James R. Kasinger
General Counsel and Secretary
Oct 6, 2026Option exercise+1,990$13.62$27.10K96,774
James R. Kasinger
General Counsel and Secretary
Sep 22, 2026Option exercise+10,400$13.62$141.65K105,184
James R. Kasinger
General Counsel and Secretary
Sep 22, 2026Sale(10b5-1 plan)−10,400$60.24$626.50K94,784
Ali Behbahani
Director
Sep 17, 2026Option exercise+30,000$14.00$420.00K30,316
Ali Behbahani
Director
Sep 17, 2026Sale−13,679$57.09$780.93K16,637
Raju Prasad
Chief Financial Officer
Aug 7, 2026Gift−750––14,815
Naimish Patel
Chief Medical Officer
May 29, 2026Sale−3,786$55.62$210.58K19,357
Naimish Patel
Chief Medical Officer
May 28, 2026Option exercise+10,000––23,143
Raju Prasad
Chief Financial Officer
Mar 23, 2026Sale−3,708$46.78$173.46K15,565
James R. Kasinger
General Counsel and Secretary
Mar 23, 2026Sale−3,182$46.78$148.85K94,308
Samarth Kulkarni
Chief Executive Officer, Director
Mar 23, 2026Sale−10,020$46.78$468.74K255,501
Raju Prasad
Chief Financial Officer
Mar 20, 2026Option exercise+6,250––19,273
James R. Kasinger
General Counsel and Secretary
Mar 20, 2026Option exercise+6,250––97,490
Samarth Kulkarni
Chief Executive Officer, Director
Mar 20, 2026Option exercise+19,687––265,521
Raju Prasad
Chief Financial Officer
Mar 16, 2026Sale−4,021$48.26$194.05K13,773
Raju Prasad
Chief Financial Officer
Mar 16, 2026Gift−750––13,023
Raju Prasad
Chief Financial Officer
Mar 16, 2026Sale−5,848$48.26$282.22K17,794
Naimish Patel
Chief Medical Officer
Mar 16, 2026Sale−3,150$48.26$152.02K13,143
Samarth Kulkarni
Chief Executive Officer, Director
Mar 16, 2026Sale−10,349$48.26$499.44K245,834
James R. Kasinger
General Counsel and Secretary
Mar 16, 2026Sale−3,450$48.26$166.50K91,240
Raju Prasad
Chief Financial Officer
Mar 14, 2026Option exercise+10,000––16,767
Raju Prasad
Chief Financial Officer
Mar 14, 2026Option exercise+6,875––23,642
Naimish Patel
Chief Medical Officer
Mar 14, 2026Option exercise+8,125––16,293
Samarth Kulkarni
Chief Executive Officer, Director
Mar 14, 2026Option exercise+20,625––256,183
James R. Kasinger
General Counsel and Secretary
Mar 14, 2026Option exercise+6,875––94,690
Samarth Kulkarni
Chief Executive Officer, Director
Mar 11, 2026Sale−9,798$52.80$517.33K235,558
James R. Kasinger
General Counsel and Secretary
Mar 11, 2026Sale−2,800$52.80$147.84K87,815
Samarth Kulkarni
Chief Executive Officer, Director
Mar 10, 2026Option exercise+19,250––245,356
James R. Kasinger
General Counsel and Secretary
Mar 10, 2026Option exercise+5,500––90,615
James R. Kasinger
General Counsel and Secretary
Feb 19, 2026Sale−2,112$52.58$111.05K85,115
Samarth Kulkarni
Chief Executive Officer, Director
Feb 19, 2026Sale−6,967$52.58$366.32K226,106
James R. Kasinger
General Counsel and Secretary
Feb 18, 2026Option exercise+3,825––87,227
Samarth Kulkarni
Chief Executive Officer, Director
Feb 18, 2026Option exercise+13,250––233,073
Raju Prasad
Chief Financial Officer
Jan 22, 2026Sale(10b5-1 plan)−34,972$60.19$2.10M6,767
Raju Prasad
Chief Financial Officer
Jan 22, 2026Option exercise+34,972$45.15$1.58M41,739
Samarth Kulkarni
Chief Executive Officer, Director
Jan 22, 2026Sale(10b5-1 plan)−60,000$60.23$3.61M134,201
Samarth Kulkarni
Chief Executive Officer, Director
Jan 20, 2026Sale(10b5-1 plan)−8,567$52.10$446.34K194,201
Samarth Kulkarni
Chief Executive Officer, Director
Jan 20, 2026Sale(10b5-1 plan)−21,433$51.61$1.11M202,768
Raju Prasad
Chief Financial Officer
Jan 6, 2026Sale(10b5-1 plan)−18,933$60.18$1.14M17,534
Raju Prasad
Chief Financial Officer
Jan 6, 2026Sale(10b5-1 plan)−5,004$60.00$300.24K12,530
Raju Prasad
Chief Financial Officer
Jan 6, 2026Sale(10b5-1 plan)−5,763$60.21$346.99K6,767
Raju Prasad
Chief Financial Officer
Jan 6, 2026Option exercise+6,339$44.31$280.88K36,467
Raju Prasad
Chief Financial Officer
Jan 6, 2026Option exercise+23,361$45.15$1.05M30,128
Raju Prasad
Chief Financial Officer
Dec 22, 2025Sale(10b5-1 plan)−5,472$56.33$308.24K7,767
Raju Prasad
Chief Financial Officer
Dec 22, 2025Sale(10b5-1 plan)−1,000$56.89$56.89K6,767
Raju Prasad
Chief Financial Officer
Dec 22, 2025Sale(10b5-1 plan)−3,528$55.10$194.39K13,239
Samarth Kulkarni
Chief Executive Officer, Director
Dec 18, 2025Gift−30,000––224,201
Samarth Kulkarni
Chief Executive Officer, Director
Oct 17, 2025Sale−50,895$67.91$3.46M254,201
Samarth Kulkarni
Chief Executive Officer, Director
Oct 16, 2025Option exercise+100,000––305,096
James R. Kasinger
General Counsel and Secretary
Oct 14, 2025Sale−1,076$66.60$71.66K83,402
Samarth Kulkarni
Chief Executive Officer, Director
Oct 14, 2025Sale−4,242$66.60$282.52K205,096

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
18.27%
17M shares short
Days to cover
13.1
At 1M shares a day
Change since last report
+4.5%
From 16M shares
Short volume, 20 days
54.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of CRISPR Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 36,884 shares on Oct 7, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Raju Prasad
Officer
Nov 6, 202679,393$3.96MNov 6, 2026Stock Option Exercise
Simeon George
Director
Oct 14, 202614,514$720.37KOct 14, 2026Stock Option Exercise
James R. Kasinger
Officer
Oct 6, 20261,990$119.48KOct 6, 2026Stock Option Exercise
James R. Kasinger
Officer
Sep 22, 202610,400$626.46KSep 22, 2026Stock Option Exercise
Ali Behbahani
Director
Sep 17, 202613,679$780.94KSep 17, 2026Stock Option Exercise
Raju Prasad
Officer
Jan 22, 202634,972$2.11MJan 22, 2026Stock Option Exercise
Samarth Kulkarni
Officer
Jan 22, 202660,000$3.65MJan 22, 2026Acquired as compensation -- Restricted Stock Awards
Samarth Kulkarni
Officer
Jan 20, 202630,000$1.58MJan 20, 2026Acquired as compensation -- Restricted Stock Awards
Raju Prasad
Officer
Jan 6, 202629,700$1.79MJan 6, 2026Stock Option Exercise
Raju Prasad
Officer
Dec 22, 202510,000$559.55KDec 22, 2025Restricted Stock
Samarth Kulkarni
Officer
Feb 18, 202545,000$2.35MFeb 18, 2025Acquired as compensation -- Restricted Stock Awards
Samarth Kulkarni
Officer
Nov 12, 202475,000$4.11MNov 11, 2024Acquired as compensation -- Restricted Stock Awards
Samarth Kulkarni
Officer, Director
Apr 15, 202419,582$1.17MApr 15, 2024Stock Option Exercise
Phuong Khanh Morrow
Officer
Mar 22, 202450,767$3.70MMar 22, 2024Stock Option Exercise
Samarth Kulkarni
Officer, Director
Mar 15, 202420,000$1.45MMar 15, 2024Stock Option Exercise

See a number that looks wrong?